Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors

Circulation: Heart Failure

Volumn 2, Issue 2, 2009, Pages 121-128

  Mobine, Hector R ^a   Baker, Aaron B ^a   Wang, Libin ^b   Wakimoto, Hiroko ^b   Jacobsen, Kurt C ^b   Seidman, Christine E ^b,c   Seidman, J G ^b   Edelman, Elazer R ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiomyopathy; Catecholamines; Heartfailure; Norepinephrine

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOLAMINE; COLLAGEN TYPE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL ISOLATION; CELL SECRETION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE EXPRESSION; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CELL; MALE; MOUSE; MUSCLE FIBER CONTRACTION; NEWBORN; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ADRENAL GLAND NEOPLASMS; ANIMALS; CARDIOMYOPATHIES; CATECHOLAMINES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; HEART; MICE; MICE, INBRED STRAINS; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; NEOPLASM TRANSPLANTATION; NOREPINEPHRINE; PC12 CELLS; PHEOCHROMOCYTOMA; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 77953676379     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.813261     Document Type: Article

References (40)

1. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003; 24:539 -553.
2. Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem. 2003; 49:586 -593.
3. Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens. 2006; 24: 2331-2339.
4. Gifford RW Jr, Bravo EL, Manger WM. Diagnosis and management of pheochromocytoma. Cardiology. 1985; 72(suppl 1):126 -130.
5. Wilkenfeld C, Cohen M, Lansman SL, Courtney M, Dische MR, Pertsemlidis D, Krakoff LR. Heart transplantation for end-stage cardiomyopathy caused by an occult pheochromocytoma. J Heart Lung Transplant. 1992; 11:363-366.
6. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985; 17: 291-306.
7. Wheatley AM, Thandroyen FT, Opie LH. Catecholamine-induced myocardial cell damage: catecholamines or adrenochrome. J Mol Cell Cardiol. 1985; 17:349 -359.
8. Downing SE, Chen V. Myocardial injury following endogenous catecholamine release in rabbits. J Mol Cell Cardiol. 1985; 17:377-387.
9. Blaiklock RG, Hirsh EM, Dapson S, Paino B, Lehr D. Epinephrine induced myocardial necrosis: effects of aminophylline and adrenergic blockade. Res Commun Chem Pathol Pharmacol. 1981; 34:179 -192.
10. Chappel CI, Rona G, Balazs T, Gaudry R. Comparison of cardiotoxic actions of certain sympathomimetic amines. Can J Biochem Physiol. 1959; 37:35- 42.
11. Downing SE, Lee JC. Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy. Circ Res. 1983; 52: 471-478.
12. Mehes G, Papp G, Rajkovits K. Effect of adrenergic alpha- and betareceptor blocking drugs on the myocardial lesions induced by sympathomimetic amines. Acta Physiol Acad Sci Hung. 1967; 32:175-184.
13. Laycock SK, McMurray J, Kane KA, Parratt JR. Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol. 1995; 26:584 -589.
14. Warren S, Chute RN. Pheochromocytoma. Cancer. 1972; 29:327-331.
15. Mann DL, Kent RL, Parsons B, Cooper GT. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992; 85: 790-804.
16. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998; 98:1329 -1334.
17. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, Zimmer HG. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res. 2001; 52:265-273.
18. Simons M, Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J. 1985; 109:297-304.
19. Kahn DS, Rona G, Chappel CI. Isoproterenol-induced cardiac necrosis. Ann N Y Acad Sci. 1969; 156:285-293.
20. Ferrans VJ, Hibbs RG, Black WC, Weilbaecher DG. Isoproterenolinduced myocardial necrosis. A histochemical and electron microscopic study. Am heart J. 1964; 68:71-90.
21. Yoshida K, Sasaguri M, Kinoshita A, Ideishi M, Ikeda M, Arakawa K. A case of a clinically " silent" pheochromocytoma. Jpn J Med. 1990; 29: 27-31.
22. Rosenbaum JS, Billingham ME, Ginsburg R, Tsujimoto G, Lurie KG, Hoffman BB. Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. Am J Cardiovasc Pathol. 1988; 1:389 -399.
23. Tsujimoto G, Manger WM, Hoffman BB. Desensitization of betaadrenergic receptors by pheochromocytoma. Endocrinology. 1984; 114: 1272-1278.
24. Rosenbaum JS, Ginsburg R, Billingham ME, Hoffman BB. Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma. J Pharmacol Exp Ther. 1987; 241:354 -360.
25. Ohta S, Lai EW, Taniguchi S, Tischler AS, Alesci S, Pacak K. Animal models of pheochromocytoma including NIH initial experience. Ann N Y Acad Sci. 2006; 1073:300 -305.
26. Tischler AS. Chromaffin cells as models of endocrine cells and neurons. Ann N Y Acad Sci. 2002; 971:366 -370.
27. Khademhosseini A, May MH, Sefton MV. Conformal coating of mammalian cells immobilized onto magnetically driven beads. Tissue Eng. 2005; 11:1797-1806.
28. Roberts T, De Boni U, Sefton MV. Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer. Biomaterials. 1996; 17:267-275.
29. Dixon DN, Loxley RA, Barron A, Cleary S, Phillips JK. Comparative studies of PC12 and mouse pheochromocytoma-derived rodent cell lines as models for the study of neuroendocrine systems. In Vitro Cell Dev Biol Anim. 2005; 41:197-206.
30. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386.
31. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, Lee TY, Kiani C, Mickle DA, Strauss BH, Li RK. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol. 2003; 284:H626-H634.
32. Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK, Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation. 2004; 110:2401-2409.
33. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999; 79:215-262.
34. Favia G, Lumachi F, Polistina F, D'Amico DF. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg. 1998; 22:689-693; discussion 694.
35. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail. 2004; 6:41- 45.
36. Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol. 1994; 1:229 -246.
37. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998; 97:1136 -1143. (Pubitemid 28152886)
38. Lehmann MH, Kuhnert H, Muller S, Sigusch HH. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytokine. 1998; 10:739 -746.
39. Specht H, Peterziel H, Bajohrs M, Gerdes HH, Krieglstein K, Unsicker K. Transforming growth factor beta2 is released from PC12 cells via the regulated pathway of secretion. Mol Cell Neurosci. 2003; 22: 75- 86.
40. Moller JC, Kruttgen A, Burmester R, Weis J, Oertel WH, Shooter EM. Release of interleukin-6 via the regulated secretory pathway in PC12 cells. Neurosci Lett. 2006; 400:75-79.